Fisetin
Aliases: Fisatin
Last verified: 2026-09-23
The short version
A flavonoid (strawberries, apples) — the most potent natural senolytic in preclinical screens; extends mouse lifespan. RCTs ongoing (AFFIRM-Lite etc.). Status: in clinical trials. Legal supplement.
Identity & type
- Molecular type
- mali molekul
- Origin
- A flavonoid (strawberries, apples) — the most potent natural senolytic in preclinical screens; extends mouse lifespan.
Mechanism of action
Senolytic + antioxidant/anti-inflammatory action; inhibition of multiple pro-aging pathways (mTOR, NF-κB).
Dosing & routes
Official / clinical context
No approved official document exists for Fisetin. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: ~20 mg/kg/day for 2 days (intermittent); supplements 100–500 mg/day. Popular as a "safe senolytic": subtle effects on energy and joints at intermittent high doses; cheap and available.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Popular as a "safe senolytic": subtle effects on energy and joints at intermittent high doses; cheap and available.
Protocol — official vs community
Official / label
No approved use. Senolytic-flavored trials used high intermittent doses (~20 mg/kg/day for 2–3 consecutive days) extrapolated from mouse work.
- 01Intermittent high-dose days only
Duration: Course-based, months between courses in trials.
The intermittent pattern distinguishes senolytic intent from generic antioxidant use.
Community (anecdotal)
Either continuous low-dose (100–500 mg/day) or intermittent high-dose (1,000–2,000 mg/day ×2–3 days) 'senolytic pulse'.
- Cycle:
- Pulse courses every 1–6 months.
- Break:
- Built into the pulse schedule.
The two community patterns (chronic low vs intermittent high) reflect two different theories of fisetin — nobody knows which is right.
Human evidence
Mayo Clinic RCT program; preclinical lifespan extension ~10%.
Preclinical evidence
Preclinical literature preceded the clinical trials; details vary by compound.
Known risks
- Excellent tolerability.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term safety in off-label use
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.